Status:
COMPLETED
Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer
Lead Sponsor:
Wake Forest University Health Sciences
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lung Cancer
Eligibility:
All Genders
18-120 years
Phase:
PHASE2
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Givin...
Detailed Description
OBJECTIVES: Primary * Determine the response rate of patients with recurrent stage IIIB and IV non-small cell lung cancer treated with gemcitabine hydrochloride and docetaxel. * Determine the overal...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed stage IIIB or IV non-small cell lung cancer, including any of the following types:
- Squamous cell carcinoma
- Adenocarcinoma, including bronchoalveolar cell adenocarcinoma
- Large cell anaplastic carcinoma, including giant and clear cell carcinomas
- Histologic or cytologic documentation of recurrence is required
- Measurable or evaluable disease, defined as any mass reproducibly measurable in 2 perpendicular diameters by physical examination or imaging
- The following lesions are not considered measurable or evaluable:
- Bone disease only
- Pleural or pericardial effusions
- Previously irradiated lesions, unless subsequent progression is documented
- CNS metastases allowed provided the patient undergoes at least 2 weeks of radiotherapy prior to study entry
- PATIENT CHARACTERISTICS:
- Not pregnant or nursing
- Fertile patients must use effective contraception
- Negative pregnancy test
- CALGB performance status ≤ 1
- Life expectancy ≥ 3 months
- Granulocyte count \> 1,500/mm\^3
- Platelet count ≥ 100,000/mm\^3
- Creatinine ≤ 2 times normal
- Bilirubin normal
- SGOT and/or SGPT ≤ 2.5 times upper limit of normal (ULN) AND alkaline phosphatase ≤ 1.5 times ULN OR
- Alkaline phosphatase 4 times ULN and SGOT and/or SGPT normal
- Ejection fraction normal by ECHO or MUGA
- No history of congestive heart failure
- No psychiatric illness that would preclude study compliance
- No serious medical or psychiatric illness that would preclude giving informed consent or limit survival to \< 3 months
- No active uncontrolled bacterial, fungal, or viral infection
- No other malignancy within the past 5 years except curatively treated carcinoma in situ of the cervix or breast, basal cell or squamous carcinoma of the skin, or other surgically resected non-recurrent primary tumor not treated with adjuvant radiotherapy or chemotherapy
- No pre-existing peripheral neuropathy ≥ grade 2
- PRIOR CONCURRENT THERAPY:
- At least 2 weeks since prior major surgery and recovered from acute effects
- At least 2 weeks since prior palliative radiotherapy and recovered from acute toxic effects
- Any persistent toxicity (e.g., alopecia or hyperpigmentation) not associated with clinical morbidity allowed
- No prior chemotherapy
- No concurrent cranial or thoracic radiation therapy
- No concurrent cytotoxic or hormonal therapy
- Concurrent palliative radiotherapy allowed for relief of localized pain and obstruction
Exclusion
Key Trial Info
Start Date :
November 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00278460
Start Date
November 1 2000
End Date
September 1 2007
Last Update
January 19 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.